Study of QT-Prolonging Medications and Risk of Major Heart Events in Hospitalized Adults

What this Trial Is About

This research aims to understand whether medications known to prolong the QT interval QTPmeds actually increase the risk of major adverse cardiac events MACE in hospitalized adult patients. These medications are widely flagged in healthcare settings due to potential serious heart risks, but the evidence linking them to real harms is limited. The study uses a large database of nearly one million adult hospital patients from Ontario to explore this important patient safety issue. Researchers will also apply machine learning to identify which patient or treatment factors best predict these risks. The study compares patients exposed to known QT-prolonging drugs during hospitalization with those who were not exposed. Data from the Ontario GEMINI network and Epic-Dovetale electronic medical records EMRs will be analyzed, focusing on events such as death, cardiac arrest, ventricular arrhythmias, and syncope occurring up to about four weeks after first drug exposure. The study will examine time periods when patients were exposed or not exposed to these medications during the same hospital stay to better estimate risk. Participants will be adult patients admitted to participating hospitals between December 2017 and March 2025. Researchers will review anonymized hospital EMR data, including medication exposures and outcomes. They will measure the occurrence of major cardiac events and use advanced data methods to predict risk factors. The study seeks to improve the accuracy of medication alerts, enhance patient safety, and reduce unnecessary healthcare disruptions related to these drug warnings.

Do QT-Prolonging Drugs Cause Major Adverse Cardiac Events in Hospitalized Adults?